At baseline, most patients (97%) were treated with one or more glucose-lowering medications, including metformin (76%), insulin (51%), SGLT-2i (27%), sulfonylurea (29%), and DPP-4i (23%) with CV disease and risk factors managed with lipid-lowering medications (89%), platelet-aggregation inhibitors including aspirin (77%), angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (79%), and beta blockers (64%)
mood swings
It can also be combined with a mastopexy to give a better shape while tightening up the skin
Brand-name tirzepatide (Mounjaro, Zepbound) can remain at room temperature, up to 86 degrees Fahrenheit, for up to 21 cumulative days
Smaller cohort mechanistic studies provide indirect evidence that is suggestive of favourable fibrotic cardiac remodelling